about
Subanesthetic concentrations of isoflurane suppress learning as defined by the category-example task.The anesthetic effect of air at atmospheric pressure.Isoflurane anesthesia and pressure antagonism in mice.Nonlinear antagonism of anesthesia in mice by pressure.Potencies of convulsant drugs in mice selectively bred for resistance and susceptibility to nitrous oxide anesthesia.The minimum alveolar concentration of nitrous oxide in man.What solvent best represents the site of action of inhaled anesthetics in humans, rats, and dogs?Determination of anesthetic requirement in rats.Effect of nitrous oxide on folate and vitamin B12 metabolism in patients.Nitrous oxide inactivates methionine synthetase in human liver.Is there a cutoff in anesthetic potency for the normal alkanes?Anesthesia by n-alkanes not consistent with the Meyer-Overton hypothesis: determinations of the solubilities of alkanes in saline and various lipids.Nonanesthetics can suppress learning.Anesthetic and convulsant properties of aromatic compounds and cycloalkanes: implications for mechanisms of narcosis.Hypothesis: inhaled anesthetics produce immobility and amnesia by different mechanisms at different sites.Carbon monoxide production from degradation of desflurane, enflurane, isoflurane, halothane, and sevoflurane by soda lime and Baralyme.Desflurane animal and human pharmacology: aspects of kinetics, safety, and MAC.Fentanyl, clonidine, and repeated increases in desflurane concentration, but not nitrous oxide or esmolol, block the transient mydriasis caused by rapid increases in desflurane concentration.Repetitive rapid increases in desflurane concentration blunt transient cardiovascular stimulation in humans.Fentanyl, esmolol, and clonidine blunt the transient cardiovascular stimulation induced by desflurane in humans.Cardiovascular stimulation induced by rapid increases in desflurane concentration in humans results from activation of tracheopulmonary and systemic receptors.Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration.Fetal injury and abortion associated with occupational exposure to inhaled anesthetics.A glossary of anesthetic jargon.Convulsions in mice after anesthesia.Bactericidal effects of anesthetics.A review of the present status of nitrous oxide.The pharmacology of isoflurane.Tolerance of mice to nitrous oxide.The effect of acid-base balance on neostigmine antagonism of d-tubocurarine-induced neuromuscular blockade.MAC expanded: AD50 and AD95 values of common inhalation anesthetics in man.Physicochemical properties and pharmacodynamics of desflurane.Economic analysis and pharmaceutical policy: a consideration of the economics of the use of desflurane.New drugs in anesthesia.New inhaled anesthetics.Current and future perspectives on inhaled anesthetics.Hyperthermia and halothane MAC in the dog.New inhalational agents--desflurane and sevoflurane.The effects of hyperthermia and hypothermia on the rate of of induction of anesthesia: calculations using a mathematical model.Ventilatory and cardiovascular effects of enflurane anesthesia during spontaneous ventilation in man.
P50
Q30537771-37ADFBB9-6893-43A4-93F3-AA87827B975FQ33423091-F06E5C46-AAB9-49D8-9556-64832E5E4ABEQ33478839-866560CC-F9FC-42EF-9D94-60C0B5FBEFBCQ33479405-158350F7-5B53-44E6-BF70-B3E0B63D865BQ33482657-E5BB5E6C-16B0-436F-958B-1AEAF99170DFQ33483013-D43BA1C0-F1FE-48C7-8B56-83FF17AE75C5Q34100480-9A13E65C-C140-4704-98DE-0C2A2F82E768Q34219061-EAA5CCC1-12EB-40F0-97E5-BB0C7B25A78CQ34260308-FC5ADFD1-4452-4E74-8898-DB29A9EA5814Q34281261-5FDF32FA-B752-4CFF-8F9D-909AC33C68EDQ34350429-7E89E1F8-FCAB-40CE-8431-03BD5F0B213DQ34350435-529F3810-0775-4F3E-8A74-14E536C99708Q34371551-71432820-4C81-4156-91A6-2D671C8DC53AQ34405104-2D41EF70-F11D-4344-A05B-00ADE30B6E9AQ34420427-6D024535-542F-4001-9158-383BF57F0A18Q34722385-7042BE94-A7FB-443E-BF1F-1A9301293A1BQ35830356-F5549BF0-9C8F-429A-A494-399F8ED84F47Q36688057-66C5757B-8E3E-4CB4-B731-41647F92DAC6Q36725066-01A9DF78-6F57-42F5-8997-5596335AD70EQ36730016-38D84BC4-01FB-4546-A391-EE1F491DA3D5Q36787859-30D7A2CD-756D-43DD-84D3-6079EAAEA430Q36792184-B000A742-22FF-4A5B-91B3-BADED40090E2Q37298407-9ED39D6E-2BA2-4FA8-9A59-E6F0002B4491Q38482948-461A8ED6-8302-4D2F-87C2-74116211F8B1Q39255150-F2897B06-3CC0-4142-B6A7-AD5080970B1CQ39658500-F4307362-B5DB-4F25-BAC2-C7215940F6B3Q39780384-55876A12-F634-4045-BD83-4D7BBFA3A439Q40196071-AA369B20-734C-406D-8D53-4B662CB8E945Q40268670-63F14C45-FAA6-4CDC-91FD-C375137B21C1Q40310817-7AD64D50-22A7-4FDD-B3F9-9F981B6C04F2Q40310821-60263902-95DD-4AF3-9947-F615EAFC2316Q40374050-29363FC4-6584-4914-B788-C2AA30505FEBQ40374067-118DB5ED-BE99-40AF-B084-91FF25D32830Q40460620-9910610C-1E53-4255-871A-646C29F10FAEQ40667854-8B95D397-9740-4E40-A5F5-2B4533FA25E4Q40841234-68A0EA25-614D-4E55-A1E8-0718AB6BB7AEQ40902151-CD702A53-92CB-44B1-80BA-FC64BB050EB3Q40910455-40126B42-ACE4-4A90-B5A4-E856050380A6Q40929891-51DA8AA1-7763-47A6-BA30-6EE4ADDE1802Q40988049-1DE487D7-E498-4DF0-9BA9-73EE66A7CD11
P50
name
Edmond Eger, II
@ast
Edmond Eger, II
@en
Edmond Eger, II
@nl
type
label
Edmond Eger, II
@ast
Edmond Eger, II
@en
Edmond Eger, II
@nl
prefLabel
Edmond Eger, II
@ast
Edmond Eger, II
@en
Edmond Eger, II
@nl
P19
P31
P569
1930-09-03T00:00:00Z
P570
2017-08-26T00:00:00Z
P6023
2121480037